Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Ethyl eicosapentaenoic acid - Matinas BioPharma

Next Previous
X
Search
Drug Profile

Ethyl eicosapentaenoic acid - Matinas BioPharma

Alternative Names: LYPDISO™; MAT-9001; Omega 3 pentaenoic acid

Latest Information Update: 28 Jan 2022

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Matinas BioPharma
  • Class Antidementias; Antidepressants; Antihyperlipidaemics; Antineoplastics; Antiplatelets; Antivirals; Eicosanoids; Esters; Omega 3 fatty acids; Reactive oxygen species; Small molecules; Vascular disorder therapies
  • Mechanism of Action Phospholipase A2 inhibitors; Platelet aggregation inhibitors; Triglyceride modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Hypertriglyceridaemia
  • No development reported Dyslipidaemias

Most Recent Events

  • 28 Jan 2022 No recent reports of development identified for preclinical development in Dyslipidaemias(Combination therapy) in USA (PO)
  • 09 Sep 2021 Matinas BioPharma and Covance withdraws the phase III AMPLIFY trial for Hypertriglyceridaemia (PO) (NCT04662528)
  • 29 Mar 2021 Matinas BioPharma completes a phase II ENHANCE-IT trial for Hypertriglyceridemia in USA (PO) prior to March 2021

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top